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Introduction {#sec005}
============

Pulmonary hypertension (PH) is a syndrome resulting from multiple clinical conditions and disorders. Pulmonary arterial hypertension (PAH), corresponding to Group 1 of the Nice classification, is a group of diseases directly affecting pulmonary arterial resistance. PAH includes idiopathic PAH (IPAH), congenital heart disease-associated PH and connective tissue disease-associated PH \[[@pone.0227775.ref001], [@pone.0227775.ref002]\].

PAH is the fourth leading cause of the necessity for lung transplantation worldwide \[[@pone.0227775.ref003]\]. Although the recent development of medications to lower pulmonary arterial pressure (PAP) has substantially improved the prognosis of PAH \[[@pone.0227775.ref004]\], about 10% of PAH patients were reported to die within one year after the diagnosis \[[@pone.0227775.ref005]\]. The prognosis is especially poor for those with persistently high PAP despite extensive therapy \[[@pone.0227775.ref006]\], and considered for the candidates of lung transplantation \[[@pone.0227775.ref002]\]. While lung transplantation has been established as a therapeutic option for advanced PAH, interventions that can improve the hemodynamics are also required for those on the waiting-list for lung transplantation.

Disturbance in gas exchange is one of the major disorders in PH patients \[[@pone.0227775.ref002]\]. Previous studies showed that hypoxia and hypercapnia worsen PAH \[[@pone.0227775.ref007]\]. Indeed, hypoxia causes constriction of the pulmonary artery and increases PAP \[[@pone.0227775.ref008]\]. Similarly, hypercapnia also contributes to the elevation of PAP, and it has been proposed that increases in pulmonary vascular resistance (PVR) and cardiac output (CO) additively work as the pathogenesis of PAH(11--13). In addition, respiratory acidosis due to high CO~2~ partial pressure can also cause PAP escalation \[[@pone.0227775.ref009], [@pone.0227775.ref010]\].

While the disturbance in pulmonary function causes alveolar hypoventilation and chronic CO~2~ retention, sleep disordered breathing (SDB), including sleep apnea syndrome (SAS), may result in nocturnal hypoventilation and hypercapnia \[[@pone.0227775.ref011]\]. Previous studies suggested that SAS as well as nocturnal hypercapnia were associated with the escalation of PAP \[[@pone.0227775.ref012]--[@pone.0227775.ref014]\] and that positive pressure ventilation during sleep could lower daytime PAP \[[@pone.0227775.ref015]--[@pone.0227775.ref017]\]. In addition, SAS is a common morbidity for patients with PAH \[[@pone.0227775.ref018]\], thus nocturnal hypercapnia due to SDB may play a significant role in the pathogenesis of PAH. However, thus far no study has investigated the associations between nocturnal hypercapnia and clinical indices for refractory PAH patients so far.

The objective of this study is to evaluate the clinical relevance of nocturnal hypercapnia in advanced PAH being considered for lung transplantation. We hypothesized that nocturnal hypercapnia would be associated with worsened PH in these most severely affected patients. We evaluated nocturnal hypercapnia by using a transcutaneous carbon dioxide partial pressure (PtcCO~2~) monitoring system, and investigated the associations of nocturnal hypercapnia with clinical and hemodynamic parameters.

Materials and methods {#sec006}
=====================

Study patients {#sec007}
--------------

We reviewed 246 consecutive cases that were referred to Kyoto University Hospital for the evaluation of suitability for lung transplantation from January 2010 to December 2017. We identified 17 patients who were classified as having Group 1 PH according to the current guidelines \[[@pone.0227775.ref002]\]. The diagnosis of PAH was made at the primary hospitals, and confirmed at Kyoto University. We then identified 13 patients whose pre-operative whole-night PtcCO~2~ monitoring data were available and performed further analyses. We included patients irrespective of whether they were ultimately enrolled as candidates for lung transplantation. For all included cases right heart catheterization was performed, and those with post-capillary PH or thromboembolic pulmonary hypertension was excluded. High-resolution computed tomography was performed in all cases and patients with any comorbid lung diseases that might result in PH were denied as study patients. Written informed consent was obtained from most of the study participants. For the patients whose contact information was lost, we announced the conduct of this study on our institutional website and asked to contact us if they disagreed with our data access. The Kyoto University Hospital Institutional Review Board approved this study including ethical policy for data access (R1287).

Continuous evaluation of PtcCO~2~ {#sec008}
---------------------------------

According the manual of the American Academy of Sleep Medicine (AASM), we used PtcCO~2~ as a surrogate measurement of PaCO~2~ \[[@pone.0227775.ref019]\]. We utilized the TOSCA device (TOSCA measurement system and TOSCA 500 monitor, Linde Medical Sensors, Basel, Switzerland) because it has been demonstrated to have good accuracy in adult patients compared with blood gas analysis \[[@pone.0227775.ref020]--[@pone.0227775.ref022]\]. SpO~2~ was simultaneously monitored. Nocturnal hypercapnia was diagnosed according to the guidelines of AASM; i.e. PtcCO~2~ \>55 mmHg for ≥10 minutes or an increase in PtcCO~2~ ≥10 mmHg in comparison to an awake supine value exceeding 50 mmHg for ≥10 minutes \[[@pone.0227775.ref023]\]. Daytime hypercapnia was diagnosed in cases in which PaCO~2~ evaluated by daytime arterial blood gas (ABG) sampling at rest was higher than 45 mmHg. ABG data from samples obtained at the nearest day to the PtcCO~2~ monitoring were utilized for the analysis.

Data collection and analysis {#sec009}
----------------------------

The clinical data were retrospectively collected from medical records. Patients were grouped according to the presence or absence of nocturnal hypercapnia. Analyzed parameters included results of right heart catheterization, pulmonary function tests and laboratory tests. The correlations between right heart catheter parameters and mean nocturnal PctCO~2~ were also evaluated. Data from the nearest day to the PtcCO~2~ monitoring were utilized for the analyses.

Statistical analyses {#sec010}
--------------------

Data are summarized as median (range) and number (percentage). We considered that the number of study patients was too small to determine whether each parameter followed normal distribution or not, therefore we employed non-parametric statistics for analyses. Fisher's exact test, Mann-Whitney's U test and Spearman's rank correlation test were used as appropriate. EZR (Saitama Medical Centre, Jichi Medical University, Saitama, Japan) \[[@pone.0227775.ref024]\], which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria), or GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, CA, USA, [www.graphpad.com](http://www.graphpad.com)) was used for statistical analyses. A *P*-value less than 0.05 was determined to be statistically significant.

Results {#sec011}
=======

Characteristics of patients with and without nocturnal hypercapnia {#sec012}
------------------------------------------------------------------

Thirteen PAH patients with available overnight PtcCO2 measurements were identified for this study. Among them, eight patients were registered for cadaveric lung transplantation, three patients received living-donor lung transplantation, one patient died shortly after the evaluation before the registration and the other patient was not registered due to an improved response to medical treatment. As shown in [Table 1](#pone.0227775.t001){ref-type="table"}, six out of 13 patients (46.2%) had nocturnal hypercapnia (representative test results are presented in [S1 Fig](#pone.0227775.s001){ref-type="supplementary-material"}). There were no differences between patients with and without nocturnal hypercapnia in terms of age, sex, body mass index or blood BNP level. The treatment procedure was also similar, although the introduction of intravenous epoprostenol treatment was relatively frequent in patients with nocturnal hypercapnia (86.6% vs. 28.6%, P = 0.103). Two patients had received prior chest surgery, both of which were repair surgery for congenital heart diseases, neither of these patients exhibited nocturnal hypercapnia.

10.1371/journal.pone.0227775.t001

###### Background data on study patients.

![](pone.0227775.t001){#pone.0227775.t001g}

                                          Nocturnal hypercapnia (-)   Nocturnal hypercapnia (+)   *P*-value
  --------------------------------------- --------------------------- --------------------------- -----------
  Number                                  7                           6                           
  Age                                     31.00 \[12.00, 59.00\]      26.00 \[14.00, 53.00\]      0.568
  Male sex (%)                            3 \[42.9\]                  0 \[0.0\]                   0.192
  Diagnosis                               IPAH:1                      Eisenmenger synd: 1         
  Systemic sclerosis: 1                                                                           
  Takayasu Disease: 1                                                                             
  PVOD: 1                                 IPAH:5                                                  
  Eisenmeger synd: 3                                                                              
  Previous thoracic surgery               2                           0                           0.462
  Nasal 0xgen supplementation (L/min)     2.00 \[1.00, 7.00\]         2.00 \[1.00, 4.00\]         0.348
  Body mass index                         18.37 \[15.35, 25.57\]      18.19 \[13.29, 30.32\]      0.886
  Treatment                                                                                       
      Number of oral anti-PH medication   2.00 \[1.00, 4.00\]         2.00 \[1.00, 3.00\]         0.879
      Diuretics usage                     6 \[85.7\]                  5 \[83.3\]                  \>0.99
      IV Epoprostenol usage               2 \[28.6\]                  5 \[83.3\]                  0.103
      IV Epoprostenol dose (ng/kg/min)    35.5 \[0.9, 70\]            51.0 \[45, 200.0\]          0.571
  Laboratory tests                                                                                
      BNP (pg/ml)                         98.70 \[11.90, 586.90\]     127.90 \[10.10, 170.50\]    0.465
      Hemoglobin (g/dl)                   12.00 \[10.00, 24.70\]      11.30 \[9.30, 19.90\]       0.431
  Lung transplantation                    2 \[28.6\]                  3 \[50.0\]                  0.592
  Death                                   2 \[28.6\]                  0 \[0.0\]                   0.462

Data are presented as number \[%\] or median \[range\]. Mann-Whitney's U-test or Fisher's exact test was used for statistical analyses. IPAH: idiopathic pulmonary arterial hypertension, PVOD: pulmonary venous occlusive disease.

All patients were receiving long-term oxygen therapy. Differences in the rates of death and/or transplantation were not significant.

Notably, of the 6 patients with nocturnal hypercapnia, 5 had IPAH (83.3%). A comparison of the mean and maximum PtcCO~2~ levels at night between IPAH patients and non-IPAH patients showed that mean and maximum PtcCO~2~ at night were significantly higher among the IPAH patients ([Fig 1](#pone.0227775.g001){ref-type="fig"}).

![Mean PtCO~2~ in non-IPAH and IPAH patients.\
Box plots indicating mean (A) or maximum (B) values of PtcCO~2~ among IPAH (n = 6) or non-IPAH (n = 7) patients. Whiskers indicate the highest and lowest values. *P*-values were calculated using Mann-Whitney's U-test. \*: P \< 0.05, \*\*: P \< 0.01. IPAH: idiopathic pulmonary arterial hypertension.](pone.0227775.g001){#pone.0227775.g001}

Parameters of respiratory status and pulmonary function in patients with and without nocturnal hypercapnia {#sec013}
----------------------------------------------------------------------------------------------------------

We next investigated the characteristics of the respiratory status and pulmonary function of patients with and without nocturnal hypercapnia ([Table 2](#pone.0227775.t002){ref-type="table"}). Seven of the 13 patients had a decrease in %FVC \<80%, while there were no significant differences in %FVC, %FEV1 and %DLco between the two groups. On the other hand, we found that the %TLC and %PEF in the nocturnal hypercapnia group was significantly lower than in the group without nocturnal hypercapnia; also patients with nocturnal hypercapnia had a significantly higher mean and maximum PtcCO~2~. All the patients were prescribed long-term oxygen therapy including usage during sleep. However, an increase in 3%ODI, which is generally regarded as a representative indicator of SDB, was rarely observed in either group. Daytime PaCO~2~ was equivalent in both groups, and daytime hypercapnia was not observed in any patient in the present study.

10.1371/journal.pone.0227775.t002

###### Pulmonary function tests and blood gas indices.

![](pone.0227775.t002){#pone.0227775.t002g}

                               Nocturnal hypercapnia (-)   Nocturnal hypercapnia (+)   *P*-value
  ---------------------------- --------------------------- --------------------------- -----------
  Number                       7                           6                           
  Capnometer measurements                                                              
      3%ODI (per hour)         0.35 \[0.00, 2.95\]         1.38 \[0.12, 12.02\]        0.198
      Max PtcCO~2~ (mmHg)      48.00 \[39.00, 54.00\]      73.50 \[59.00, 75.00\]      0.003
      Mean PtcCO~2~ (mmHg)     42.41 \[35.27, 47.32\]      50.70 \[47.52, 65.36\]      0.003
  Pulmonary Function tests                                                             
      %FVC                     85.05 \[56.00, 96.30\]      75.20 \[38.10, 88.90\]      0.173
      %FEV1                    79.80 \[59.80, 87.20\]      65.20 \[43.00, 87.10\]      0.109
      %DLco                    63.73 \[31.57, 90.48\]      57.38 \[32.74, 80.26\]      0.715
      %TLC                     94.10 \[88.40, 112.10\]     84.35 \[56.40, 92.20\]      0.018
      %PEF                     95.30 \[78.80, 111.90\]     78.05 \[70.20, 88.20\]      0.015
  Daytime arterial blood gas                                                           
      PaO~2~ (mmHg)            87.60 \[41.00, 121.20\]     75.65 \[56.50, 117.80\]     0.775
      PaCO~2~ (mmHg)           35.60 \[28.70, 41.60\]      38.60 \[32.80, 44.30\]      0.224
      HCO~3~^-^ (mEq/l)        22.50 \[19.70, 27.10\]      25.35 \[21.50, 27.00\]      0.199

Data are presented as median \[range\]. Mann-Whitney's U-test was used for statistical analyses.

FVC: forced vital capacity, FEV1: , DLco: , TLC: total lung capacity, PEF: peak expiratory flow, ODI: Oxygen desaturation index, PtcCO~2~: transcutaneous carbon dioxide partial pressure.

We further investigated whether mean PtcCO~2~ was associated with pulmonary function indexes. We found negative correlations between mean PtcCO~2~ at night and %TLC ([Fig 2](#pone.0227775.g002){ref-type="fig"}).

![Associations between PtCO~2~ and pulmonary function test indices.\
Scatter plots showing the correlations between mean PtcCO~2~ and %FEV1 (A), %FVC (B), %DLco (C), %TLC (D) or %PEF (E). Each dot represents one patient. Spearman's rank correlation test was used for statistical analysis. For one patient no pulmonary function data were available, and for two patients DLco and TLC data were not available. \*: P \< 0.05. FEV1: forced expiratory volume in one second, FVC: forced vital capacity, DLco: diffusing capacity for carbon monoxide, TLC: total lung capacity, PEF: peak expiratory flow.](pone.0227775.g002){#pone.0227775.g002}

Correlations between nocturnal hypercapnia and hemodynamic parameters {#sec014}
---------------------------------------------------------------------

Among the parameters of hemodynamic status, we found that the patients with nocturnal hypercapnia had a significantly higher levels of cardiac output (CO) and cardiac index (CI) measured by right heart catheterization (P = 0.012 and P = 0.015, respectively). However, there were no significant differences between groups in other right heart catheter parameters such as mean, systolic and diastolic PAP, mean PCWP and PVR ([Table 3](#pone.0227775.t003){ref-type="table"}). Investigation of the correlations between the mean PtcCO~2~ at night and the CO and CI showed strong correlations ([Fig 3A and 3B](#pone.0227775.g003){ref-type="fig"}).

![Associations between PtcCO~2~ and cardiac output or index.\
Scatter plots showing the correlations between mean PtcCO~2~ and cardiac output (A) or cardiac index (B). Each dot represents one patient. Spearman's rank correlation test was used for statistical analysis. \*\*: P \< 0.01.](pone.0227775.g003){#pone.0227775.g003}

10.1371/journal.pone.0227775.t003

###### Right heart catheter measurements in the patients with and without nocturnal hypercapnia.

![](pone.0227775.t003){#pone.0227775.t003g}

                                      Nocturnal hypercapnia (-)   Nocturnal hypercapnia (+)   P-value
  ----------------------------------- --------------------------- --------------------------- ---------
  Number                              7                           6                           
  Right heart catheter measurements                                                           
      mean PAP (mmHg)                 54.00 \[46.00, 82.00\]      57.00 \[35.00, 92.00\]      0.774
      systolic PAP (mmHg)             88.00 \[62.00, 101.00\]     95.00 \[52.00, 142.00\]     0.568
      diastolic PAP (mmHg)            30.00 \[15.00, 66.00\]      29.00 \[23.00, 70.00\]      0.886
      mean PCWP (mmHg)                9.00 \[6.00, 25.00\]        11.00 \[10.00, 13.00\]      0.126
      PVR (mmHg/L/min)                10.32 \[4.66, 23.27\]       6.31 \[4.07, 24.05\]        0.317
      Cardiac Index (L/min/m^2^)      2.66 \[1.98, 3.24\]         4.26 \[2.66, 6.97\]         0.012
      Cardiac Output (L/min)          3.97 \[2.51, 5.25\]         6.54 \[3.41, 8.43\]         0.015

Data are presented as median \[range\]. Mann-Whitney's U-test was used for statistical analyses.

PAP: pulmonary arterial pressure, PCWP: pulmonary capillary wedge pressure, PVR: pulmonary vascular resistance.

Discussion {#sec015}
==========

In the present study nocturnal hypercapnia was observed in nearly half of the PAH patients, as well as in most of those with IPAH, who were considered for lung transplantation. Mean PtcCO~2~ at night correlated negatively with %TLC. Higher PtcCO~2~ was associated with increased CO and CI. This is the first study to investigate the clinical significance of nocturnal hypercapnia in PAH patients.

Nocturnal hypercapnia results mainly from alveolar hypoventilation during sleep. The pathogenesis of nocturnal hypercapnia is comprised of the impairment of pulmonary function and an insufficient response against hypoxia/hypercapnia \[[@pone.0227775.ref011]\]. Although obesity hypoventilation syndrome is a major cause of nocturnal hypercapnia \[[@pone.0227775.ref011]\], the BMI in the majority of the current study patients was lower than normal (18.5 kg/m^2^). Previously it was revealed that a low BMI affects the respiratory muscle mass, which results in the impairment of muscle performance \[[@pone.0227775.ref025]\] and a proportional decline in respiratory pressure \[[@pone.0227775.ref026]\]. In the present study, low values for %FVC, %TLC and %PEF were the most distinct features of nocturnal hypercapnia. Total lung capacity is determined by lung elastic recoil, chest wall elastic recoil and inspiratory muscle power, whereas expiratory muscle power and airway obstruction largely affects PEF \[[@pone.0227775.ref027]\]. Given that in this study restrictive and obstructive pulmonary diseases were denied by computed tomography and pulmonary function test, and lung and chest wall elastic recoils are not changed in patients with PAH in general, the decrease in %TLC and %PEF would be due to a decline in inspiratory and expiratory muscle power, respectively \[[@pone.0227775.ref027]\]. Other potential factors for the restriction of chest movement, such as previous thoracic surgery or skin stiffness due to systemic sclerosis, were only found in the patients without nocturnal hypercapnia, suggesting that these factors did not largely affect nocturnal hypercapnia in this study. Although we could not investigate muscle mass or muscle power directly, these pulmonary function data imply that the lowered respiratory muscle power associated with a low BMI were candidate mechanisms for nocturnal hypercapnia. Recently, decreased muscle mass due to sarcopenia was shown to be frequent among lung transplantation candidates and constitute a risk factor for a poor prognosis \[[@pone.0227775.ref028]\]. In addition, inspiratory muscle power is substantially reduced during sleep, especially during rapid eye movement sleep \[[@pone.0227775.ref029]\]. Therefore, the reduction in minute ventilation which results in sleep-related hypoventilation might represent an early stage of chronic hypoventilation syndrome \[[@pone.0227775.ref011]\]. Indeed, the low values for %TLC in the study patients were associated with an elevation in mean PtcCO~2~, which suggests relationships between impairment of pulmonary function due to the respiratory muscle dysfunction in IPAH patients and nocturnal hypercapnia. In addition to the impairment in pulmonary function, previous studies suggested that in PAH patients the cerebral microvascular blood flow response against PaCO~2~ elevation is suppressed, thereby ameliorating the stimuli to breathe \[[@pone.0227775.ref030]\]. The integration of these factors may contribute to the high prevalence of nocturnal hypercapnia among IPAH patients. On the other hand, in the present study, there were no significant differences in BMI between patients with and without nocturnal hypercapnia, or between IPAH and non-IPAH patients. These results suggest that other factors had contributed to the impairment of muscle power especially in patient with nocturnal hypercapnia or IPAH patients. Therefore, further study is required to investigate the underlying pathophysiology of nocturnal hypercapnia in PAH patients.

In contrast to the high prevalence of nocturnal hypercapnia, daytime hypercapnia was not observed in any study patient, indicating that alveolar hypoventilation among PAH patients is largely limited during sleep. Recently, it was reported that noninvasive ventilation (NIV) can improve nocturnal hypercapnia in patients with nocturnal hypercapnia without daytime hypercapnia \[[@pone.0227775.ref031]\]. In addition, while alveolar hypoventilation may accompany low values for partial pressure of oxygen, the elevation of 3%ODI was rarely observed among the study patients, presumably because of treatment with oxygen supplementation. These results suggest that the assessment of either the daytime PaCO~2~ level or nocturnal SpO~2~ level is not sufficient to predict the complication of nocturnal hypercapnia in PAH patients, which highlights the significance of PtcCO~2~ monitoring at night.

Hypoxia is regarded as a significant factor in the progression of PAH and careful monitoring is generally performed \[[@pone.0227775.ref002]\]. Indeed, in the present study oxygen supplementation was introduced to all study participants and oxygen desaturation was rarely observed. On the other hand, the clinical significance of nocturnal hypercapnia/hypocapnia in PAH patients has been scarcely investigated. Physiologically, hypercapnia contributes to the escalation of PAP through several mechanisms. First, elevation of PaCO~2~ directly induces the constriction of the pulmonary vasculature, thereby increases PVR \[[@pone.0227775.ref008]\]. Second, ventilatory acidosis resulting from rapid elevation of PaCO~2~ also increases PVR \[[@pone.0227775.ref009]\]. Third, elevated PaCO~2~ increases CO, which causes the escalation of PAP \[[@pone.0227775.ref010]\]. Even though nocturnal hypercapnia is reversible, prolonged and repeated exposure of the above factors eventually enhances stiffness of pulmonary vessels and results in an increase in PVR. Indeed, obesity hypoventilation syndrome is often complicated with PH \[[@pone.0227775.ref013]\], and NIV treatment during sleep can lower daytime PAP as well as PVR in these patients \[[@pone.0227775.ref017]\], suggesting that recurrent exposure to nocturnal hypercapnia is a treatable causality of daytime PH. Therefore, we anticipate that nocturnal hypercapnia among PAH patients may constitute a significant pathogenic role in the development of PAP escalation, and its normalization is a possible strategy for treatment of PAH.

In the present study, we found a significant positive correlation between mean PtcCO~2~ levels at night and CO as well as CI. The increase in CO is a fundamental factor in the elevation of PAP; therefore it is suggested that nocturnal hypercapnia is associated with an increase in PAP. On the other hand, a correlation between mean PtcCO~2~ at night and mean PAP or PVR was not apparent. We propose two possible interpretations of these data. One is that nocturnal hypercapnia increases CO without affecting PAP or PVR. The other interpretation is that nocturnal hypercapnia induces an increase in CO and PVR, but that in these patients the PVR elevation was masked by medication. We found that the usage of epoprostenol infusions was relatively frequent and also that the dose was higher in the study patients with nocturnal hypercapnia, which could have lowered PVR. A previous study showed that CO was well correlated lineally with CO~2~ production (40). Therefore, patients with high CO would have higher CO~2~ production than patients with relative low CO. In addition to low lung function ([Table 2](#pone.0227775.t002){ref-type="table"}), the difference in CO~2~ production related to CO would partly contribute to a significant elevation in mean and max PtcCO~2~ in the patients with high CO: the patients with nocturnal hypercapnia (Tables [2](#pone.0227775.t002){ref-type="table"} and [3](#pone.0227775.t003){ref-type="table"}). Because the current study could not dissect the contribution of nocturnal hypercapnia to the hemodynamic status in PAH patients without the confounding effect of medications, a future study can be expected to investigate whether nocturnal hypercapnia affects PAP or PVR. In addition, dynamic changes of PAP in parallel with the levels of PtcCO~2~ were reported \[[@pone.0227775.ref013], [@pone.0227775.ref016]\]. Nocturnal hypercapnia was specifically observed during sleep, therefore a future study focusing on hemodynamics during sleep is expected.

Although the data sample was small, it is notable that as many as 46.2% (6/13) of PAH patients overall and 83.3% (5/6) of IPAH patients had nocturnal hypercapnia. We suppose that this high rate has been overlooked because these patients rarely manifest daytime hypercapnia. In general, the condition of PAH patients waiting for lung transplantation is refractory against full treatment with currently available medications. Considering that nocturnal hypercapnia is treatable with NIV \[[@pone.0227775.ref017], [@pone.0227775.ref031]\], we would consider that NIV during sleep could be a novel option to treat these patients. Further investigation of the use of NIV in such patients is needed.

This study has several limitations. First, due to its retrospective nature, disease severity, treatment procedures and comorbid diseases were not controlled for. In addition, because of the small number of study patients, we could not perform multivariate analysis to adjust for these variables. Second, the number of study patients was scant; thus the power to detect differences between groups may not be sufficient. Third, a detailed evaluation of sleep status (e.g. polysomnography) was not performed; therefore, precise events occurring in PAH patients during sleep were not analyzed. Especially, further investigations are required to reveal the pathophysiology affecting IPAH patients that contributed to the high frequency of nocturnal hypercapnia in this group.

In spite of these limitations, we for the first time reported that nocturnal hypercapnia was observed in nearly half of PAH patients and in the majority of IPAH patients who were considered for lung transplantation. Also revealed were possible correlations between nocturnal hypercapnia and impaired pulmonary function or altered hemodynamic status in the daytime. Further studies are needed to investigate hemodynamics during sleep and to dissect the direct effect of nocturnal hypercapnia on PAP or PVR and to evaluate whether the normalization of nocturnal hypercapnia has therapeutic significance for PAH patients.

Supporting information {#sec016}
======================

###### Representative TOSCA results for patients with nocturnal hypercapnia.

\(A\) TOSCA summary sheet for a 14-year-old female patient with IPAH and (B) 35-year-old female patient with IPAH. The intervals between the bold lines were analyzed. IPAH: idiopathic pulmonary arterial hypertension.

(TIF)

###### 

Click here for additional data file.

###### The dataset used for the analyses in this study.

(XLSX)

###### 

Click here for additional data file.
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Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Answer 1: See below

Answer 2: Yes, but should be justified (see comment below)

Answer 3: Yes, the authors indicate that the individual data sets are available only upon request; they were not available in the supplemental information or included in the original submission.

Answer 4: Yes, but there are scattered, small grammatical and document formatting errors.

\-\-\-\--

In the submission entitled, \"Nocturnal hypercapnia with daytime normocapnia in patients with advanced pulmonary arterial hypertension (PAH) awaiting lung transplantation,\" the authors describe a small cohort of patients with PAH and the incidence of nocturnal hypercapnia in this population, speculating as to the significance of this finding, as well as if it offers a possible additional therapeutic intervention in these patients.

General Comments

1\. There are scattered small, but notable grammatical errors throughout the manuscript. If revised, it would benefit from ensuring that these are corrected.

Comments on the Manuscript

1\. In general, the authors overstate their conclusions re: this population (e.g. \"it is notable that as many as 46.2% of PAH patients and 83.3% of IPAH patients were complicated by nocturnal hypercapnia\") given that the sample size / retrospective review involved such a few number of patients. When the numbers themselves are examined, this study only looked at 13 patients and each group (nocturnal hypercapnia (-) versus nocturnal hypercapnia (+) only contained 7 and 6 patients, respectively. It is very difficult to draw the firm conclusions these authors have based on these numbers alone as it is very doubtful that these small \#s would allow this review to be sufficiently powered to detect the indicated differences

2\. In the \"Methods\" section, the authors indicate the specific statistical tests used, but should be more specific (e.g. \"this test was used as the results demonstrate a non-normal distribution\" or other justification)

3\. The authors comment that \"no study has investigated the impact of nocturnal hypercapnia on refractory PAH patients so far,\" yet this study does not meet this objective; it just describes the incidence of nocturnal hypercapnia, but does not show that it actually leads to worse PAH (at least per indicated right heart catheterization numbers provided) or leads PAH that is necessarily more refractory to treatment. It also does not appear to necessarily change outcomes post-transplantation (although again, the number of patients is small)

4\. In the discussion, the authors postulate that \"lung and chest wall elastic recoil are not changed in patients with PAH\" which is true, but does not take into account that each of these individual patients may have had another factor(s) that could have modified these variables (for example, prior chest surgery) and contributed to decline in TLC (not addressed).

5\. The authors also postulate that a low BMI \"implied the existence of lower respiratory muscle mass\" - but does not give a source / animal model / other to support this conclusion. In addition, they imply that this occurs more in the IPAH patients they studied, but do not provide this data (e.g. comparison of BMI between IPAH and non-IPAH). Other data that may support this claim would be NIF / NEF as respiratory muscle weakness (if present) should also be detectable while awake

Comments on the Figures

1\. Figures should include significance markers (\*) per convention in addition to the p-values.

2\. In Figure 1 for the box-and-whisker plots, please include the individual data points within the plots and the number of patients per group. In addition, the Y-axis titles on both graphs are labeled \"mean,\" however, the text of the figures indicates one graph is the mean PtcCO2, while the other is the maximum PtcCO2.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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We thank the reviewer for his/her constructive comments. Below please find our point-by-point responses to all comments. We believe that we have examined each of the points raised and responded thoroughly. We would thank the reviewer for careful examination of our manuscript and thoughtful suggestions, which have definitely helped us to make this manuscript a better paper.

Detailed replies to specific comments are shown below.

General Comments

1\. There are scattered small, but notable grammatical errors throughout the manuscript. If revised, it would benefit from ensuring that these are corrected.

Author reply:

Thank you for the thorough check of our grammatical errors. To minimize the possibility of further errors, we have consulted a company specialized in editing medical and scientific materials written by those whose first language is not English (NAI, Inc.). We mentioned appreciation of this review in the "Acknowledgments" section.

"The authors also thank NAI.Inc for editing the English text of this manuscript."

Comments on the Manuscript

1\. In general, the authors overstate their conclusions re: this population (e.g. \"it is notable that as many as 46.2% of PAH patients and 83.3% of IPAH patients were complicated by nocturnal hypercapnia\") given that the sample size / retrospective review involved such a few number of patients. When the numbers themselves are examined, this study only looked at 13 patients and each group (nocturnal hypercapnia (-) versus nocturnal hypercapnia (+) only contained 7 and 6 patients, respectively. It is very difficult to draw the firm conclusions these authors have based on these numbers alone as it is very doubtful that these small \#s would allow this review to be sufficiently powered to detect the indicated differences

Author reply:

We appreciate the comment. To clarify the prevalence of nocturnal hypercapnia among PAH patients, we added the description of actual number of total patient number as well as the number of patients with nocturnal hypercapnia as follows;

(Abstract "Results" section, page: 2, line:13)

Of note, nocturnal hypercapnia was found for 5 out of 6 patients with idiopathic PAH (83.3%).

(Manuscript, "Results" section, page: 8, line: 8)

Notably, of the 6 patients with nocturnal hypercapnia, 5 had IPAH (83.3%).

We agree that there is a difficulty in reaching a firm conclusion with this small number of patients. Because the background of patients such as treatment procedures, age, sex and BMI varied, the adjustment of these factors through multivariate analysis would be desired, but the patient number did not allow us to do so. To clearly recognize this shortcoming, we newly added the following sentence as a limitation;

(Manuscript, "Discussion" section, page: 16, line: 16)

In addition, because of the small number of study patients, we could not perform multivariate analysis to adjust these variables.

On the other hand, we would like to emphasize that these patients were strictly selected from a large number of patients (246 patients) who were considered for lung transplantation in Kyoto University. As Kyoto University performs the largest number of lung transplantation surgery in Japan, and pre-operative evaluation of PtcCO2 is not a regular practice in institutions other than Kyoto University, we think this study included the largest number of patients currently possible Further validation of the results requires a prospective study ideally of a larger number of patients. In spite of the small number of patients, this study includes a number of clinically relevant results that were statistically significant and were supported by previous human experimental studies (e.g. the association between PtcCO2 values and cardiac output). Therefore, we believe that the data presented in this manuscript will motivate clinicians to conduct the future prospective studies to dissect the clinical impact of nocturnal hypercapnia among PAH patients.

2\. In the \"Methods\" section, the authors indicate the specific statistical tests used, but should be more specific (e.g. \"this test was used as the results demonstrate a non-normal distribution\" or other justification)

Author reply:

It is obviously beneficial to clarify the reason why we used a specific statistical test, so we appreciate the reviewer's suggestion of this modification. As the reviewer pointed out and we agreed, the number of study patients was small. For this reason we considered that it was not appropriate to determine whether each parameter followed normal distribution through statistical tests such as the Kolmogorov--Smirnov test and Shapiro-Wilk test. Therefore we decided to use non-parametric statistics for the analyses throughout the study. We added the following sentence to the "Methods" section.

(Manuscript, "Method" section, page: 7, line: 5)

"We considered that the number of study patients was too small to determine whether each parameter followed normal distribution or not, therefore we employed non-parametric statistics for analyses."

3\. The authors comment that "no study has investigated the impact of nocturnal hypercapnia on refractory PAH patients so far," yet this study does not meet this objective; it just describes the incidence of nocturnal hypercapnia, but does not show that it actually leads to worse PAH (at least per indicated right heart catheterization numbers provided) or leads PAH that is necessarily more refractory to treatment. It also does not appear to necessarily change outcomes post-transplantation (although again, the number of patients is small)

Author reply:

We are grateful for this thoughtful comment. We think this criticism largely arises from the fact that this retrospective study does not include longitudinal data that would support a causal relationship between nocturnal hypercapnia and clinical outcomes. On this point, we would like to note that this study focused on the associations between PtcCO2 values and other clinical parameters, which at least suggested the relationship between these factors. We agree that the word "impact" could have been misleading, therefore, we modified the descriptions as follows;

(Manuscript, "Introduction" section, page: 5, line: 5)

"However, thus far no study has investigated the associations between nocturnal hypercapnia and clinical indices for refractory PAH patients so far."

On the other hand, in "Discussion" section, we described the potential of nocturnal hypercapnia as a therapeutic target. This consideration was based on the results of this study as well as a previous physiological experimental study (Westcott RN, et al. J Clin Invest. 1951) and prospective study revealing the effect of NPPV on lowering the PAP (Held M, et al. Eur Respir J. 2014). Therefore we retained the description that was in the original version of this manuscript.

4\. In the discussion, the authors postulate that \"lung and chest wall elastic recoil are not changed in patients with PAH\" which is true, but does not take into account that each of these individual patients may have had another factor(s) that could have modified these variables (for example, prior chest surgery) and contributed to decline in TLC (not addressed).

Author reply:

We appreciate the comment. In this study, two patients had undergone prior chest surgery. Both surgeries were repair surgery for congenital heart diseases. We agree that the surgical procedure could have reduced the mobility of the chest wall and thereby contributed to the limitation of TLC. We added these data to Table 1. Another potential factor for low TLC was the skin stiffness of a patient with systemic sclerosis, which could restrict chest movement. However, in this study, these patients did not have nocturnal hypercapnia. Therefore, we think that the contribution of these factors would not be large for the development of nocturnal hypercapnia.

Based on these considerations, we modified the description as follows:

(Manuscript, "Results" section, page: 8, line: 3)

"Two patients had received prior chest surgery, both of which were repair surgery for congenital heart diseases, neither of these patients exhibited nocturnal hypercapnia."

(Manuscript, "Discussion" section, page: 12, line: 9)

"Other potential factors for the restriction of chest movement, such as previous thoracic surgery or skin stiffness due to systemic sclerosis, were only found in the patients without nocturnal hypercapnia, suggesting that these factors did not largely affect nocturnal hypercapnia in this study."

5\. The authors also postulate that a low BMI \"implied the existence of lower respiratory muscle mass\" - but does not give a source / animal model / other to support this conclusion. In addition, they imply that this occurs more in the IPAH patients they studied, but do not provide this data (e.g. comparison of BMI between IPAH and non-IPAH). Other data that may support this claim would be NIF / NEF as respiratory muscle weakness (if present) should also be detectable while awake

We appreciate this constructive criticism and thoughtful suggestion. The association between low BMI and the decline in respiratory muscle mass has been reported (Arora NS, et al. Am Rev Respir Dis. 1982), and concordantly, a proportional decline in respiratory pressure for the individuals with low BMI was shown (Sgariboldi D, et al. Respir Care. 2016). These studies clearly suggest that low BMI was associated with low respiratory muscle mass as well as impairment of respiratory muscle function.

Unfortunately, in the present study the data for muscle mass, NIF or NEF were not available. Instead, we additionally analyzed the pulmonary function tests according to the reviewer's suggestion and found that percent predicted peak expiratory flow (%PEF) was significantly lower for those with nocturnal hypercapnia. As %PEF is a useful indicator of expiratory flow pressure especially for those who do not have airway flow limitation, in the present study there was no patient who was complicated by an obstructive disorder. We think that this finding supports the decreased muscle strength in patients with nocturnal hypercapnia. We added the data to Table 2 and Figure 2, and modified the description in "Results" and "Discussion" sections as follows.

(Manuscript, "Results" section, page: 12, line: 1)

"In the present study, low values for %FVC, %TLC and %PEF were the most distinct features of nocturnal hypercapnia. Total lung capacity is determined by lung elastic recoil, chest wall elastic recoil and inspiratory muscle power, whereas expiratory muscle power and airway obstruction largely affects PEF \[27\]. Given that in this study restrictive and obstructive pulmonary diseases were denied by computed tomography and pulmonary function test, and lung and chest wall elastic recoils are not changed in patients with PAH in general, the decrease in %TLC and %PEF would be due to a decline in inspiratory and expiratory muscle power, respectively\[27\]."

Whereas obesity hypoventilation is one of the most frequent causalities for nocturnal hypercapnia, based on the considerations above, we think low BMI could also cause hypoventilation due to the impairment of muscle power. We added the following sentences to the "Discussion" section, and newly added references.

(Manuscript, "Discussion" section, page: 12, line: 13)

"Although obesity hypoventilation syndrome is a major cause of nocturnal hypercapnia\[11\], the BMI in the majority of the current study patients was lower than normal (18.5 kg/m2). Previously it was revealed that a low BMI affects the respiratory muscle mass, which results in the impairment of muscle performance\[25\] and a proportional decline in respiratory pressure\[26\]."

(Manuscript, "Discussion" section, page: 13, line: 11)

"Although we could not investigate muscle mass or muscle power directly, these pulmonary function data imply that the lowered respiratory muscle power associated with a low BMI were candidate mechanisms for nocturnal hypercapnia."

On the other hand, we did not find a statistically significant difference in BMI between IPHA patients and non-IPAH patients. We found that IPAH patients had a relatively higher frequency of %PEF \< 90% (5 out of 6 in IPAH and 2 out of 6 in non-IPAH), which implies the higher risk of muscle force impairment among IPAH patients compared with non-IPAH patients who had equivalent BMIs, although this difference was not statistically significant (P = 0.242). In addition, we also found no difference in BMI between patients with and without nocturnal hypercapnia as shown in Table 1. As we described in the manuscript, nocturnal hypercapnia could arise from complex mechanisms including impairment of pulmonary function and insufficient response against hypoxia/hypercapnia. Therefore further investigation is required to clarify the underlying mechanisms for the high frequency of nocturnal hypercapnia among IPAH patients and factors causing the impairment of respiratory muscle power. Based on these considerations, we added the following to the "Discussion" section:

(Manuscript, "Discussion" section, page: 14, line: 2)

"On the other hand, in the present study, there were no significant differences in BMI between patients with and without nocturnal hypercapnia, or between IPAH and non-IPAH patients. These results suggest that other factors had contributed to the impairment of muscle power especially in patient with nocturnal hypercapnia or IPAH patients. Therefore, further study is required to investigate the underlying pathophysiology of nocturnal hypercapnia in PAH patients."

(Manuscript, "Discussion" section, page: 16, line: 21)

"Especially, further investigations are required to reveal the pathophysiology affecting IPAH patients that contributed to the high frequency of nocturnal hypercapnia in this group."

Comments on the Figures

1\. Figures should include significance markers (\*) per convention in addition to the p-values.

Author reply:

We appreciate the suggestion. According to the reviewer's comment, we added the markers for all the figures.

2\. In Figure 1 for the box-and-whisker plots, please include the individual data points within the plots and the number of patients per group. In addition, the Y-axis titles on both graphs are labeled \"mean,\" however, the text of the figures indicates one graph is the mean PtcCO2, while the other is the maximum PtcCO2.

Author reply:

We thank for the reviewer to find out our error. We corrected the Y-axis titles of the right panel in Figure 1 as "maximum PtcCO2". In addition, we modified the figure to show the individual data overlaying the box-and-whisker plots.
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